IDH1 mutation status is an important molecular marker that has been used by the World Health Organization Classification of Tumors of the Central Nervous System to define GBM as IDH1-wildtype, and IDH-mutant gliomas are characterized as astrocytoma or oligodendroglioma [29]. This evidence concerns the gene IDH1 and central nervous system cancer.